http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
국제광물가격변동에 대한 몽골 경제의 대응방안 - 교역조건의 변화를 중심으로 -
박호용 한국몽골학회 2015 몽골학 Vol.0 No.43
This paper attempts to examine policy measures for reviving stagnant economy of Mongolia. Mongolian economy has been recently in a difficult situation because of downward trend in prices of minerals and presumably faced with an ordeal of protectionism. The Bank of Mongolia says mineral exports accounted for 90 percent of the country's economic growth, and recent stagnant of Mongolia has been most attributed to the downward trend in prices of minerals. According to the 12th GTA reports, G8 nations are being hit frequently by beggar-thy-neighbour policies, while small countries such as, Mongol and Korea are being harmed by protectionist measures more frequently than any other countries. The consequences shows that GDIs of China and Mongolia are recorded as lower than GDP because of negative gains of trade since 2005. This infers that the current loss of trade will be followed by a period of protection measures. We propose that we should basically prepare liberalizing measures, because Mongolia has been aimed at an open-economy export-oriented since the era of economic transition. On the other hand, we selectively prepare protecting measures because Mongolia is no longer small country in a point of view, such as mineral industry. Specific policy measures mentioned above are discussed.
2007년 St. Gallen 유방암 컨퍼런스 하이라이트
박호용 한국유방암학회 2007 Journal of breast cancer Vol.10 No.1
The 10th St. Gallen International Conference- Primary Therapy of Early Breast Cancer was held in March 2007. The St. Gallen Conferences has focused on reaching expert consensus for patient treatment selection. Three categories were affirmed by responsiveness of endocrine treatment- endocrine responsive, endocrine responsive uncertain, endocrine non-responsive. Risk assessment will be similar than previous meeting (9th meeting) - low, intermediate, and high risk categories. The Panel recommended that patients be offered endocrine therapy or trastuzumab according to endocrine responsiveness or HER2 status. Chemotherapy offered to patients according to risk assessment. For patients with endocrine responsive and HER2 negative, selection of patient for chemotherapy is major challenge. The Panel of Expert attempted to answer many questions- endocrine therapy, chemotherapy, anti-HER2 therapy, and radiation therapy. This report focused on new information related to the best use of endocrine therapy and chemotherapy.